The main task of the Zodiak Program is to create a nationwide research network between the best clinical, scientific and commercial institutions, aimed at developing personalized oncology tools for both the patient and the clinician.
deaths per year in Poland are caused by cancers
To reverse this negative trend, it is necessary to increase the availability of advanced drugs and modern diagnostics correlated with them.
This approach, known as personalized oncology, is the future of cancer treatment.
Such a space, created for the contact between the world of science and business, will facilitate the fast commercialization and implementation of developed solutions on the market.
are a universal solution to the problem of limited biological sample availability.
The Zodiak Program includes biobanking tissue and DNA of cancer samples.
The biobank complies with the Quality Management System (ISO 9001 certificate) and the guidelines for the Quality Standards for Polish Biobanks.
The research network includes various entities, both clinical and scientific units as well as commercial R&D companies in the field of diagnostics and oncology.
The program is supported by the Siepomaga Foundation and the Genetyka.bio magazine.
from idea to reality
As part of the Zodiak Program, joint research projects are focused on the genomics of breast cancer, which will be then extended to other types of cancer.
The aim of the project is to create an AI-powered diagnostic tool - PARPiNDx, designed to improve ovarian cancer patient classification, increasing their chances for successful clinical outcomes.
Read more
Breast cancer is characterized by a large diversity of biological subtypes, heterogeneity, and a complicated genetic origin, which means that the use of whole genome sequencing technology seems to have enormous cognitive and diagnostic potential there.
published as part of the Zodiak Program
The publication describes a breakthrough method of assessing the overexpression status of HER2 receptors located on the surface of cancer cells using whole genome sequencing. The introduction of this method in routine genetic diagnostics would allow for a more effective selection of patients for targeted therapy with drugs aimed at blocking HER2 overexpression.
Read more
